Brown fat has a reputation as the body’s built-in furnace, a tissue that burns calories to generate heat. But until now, nobody knew exactly which molecule flips the switch that turns it on. A research team at McGill University has identified that molecule: glycerol, one of the simplest and most abundant compounds in human metabolism.
Their study, published in Nature in May 2026, shows that glycerol binds to a specific site on an enzyme called tissue-nonspecific alkaline phosphatase (TNAP), activating it inside brown fat cells and triggering calorie-burning heat production. The surprise is what else that same activation does: it drives the mineralization process that hardens bones. One molecule, one enzyme, two functions that medicine has always treated as completely separate.
A molecular switch hiding in plain sight
Glycerol is released constantly during normal fat metabolism. Every time the body breaks down a triglyceride molecule, glycerol is one of the byproducts. The McGill team found that this familiar compound acts as what biochemists call an allosteric activator of TNAP. Rather than binding to the enzyme’s main active site, glycerol slots into a distinct region the researchers describe as the “glycerol pocket.” That binding event changes the enzyme’s shape just enough to switch it on.
Once activated, TNAP participates in what is known as the futile creatine cycle, a loop in which chemical energy is deliberately wasted as heat. Another enzyme, creatine kinase B (CKB), builds phosphocreatine; TNAP breaks it apart. The net result is that energy from food gets converted directly into warmth rather than stored or used for cellular work. A 2025 paper in Nature Communications had already mapped this cycle as a calorie-burning pathway in brown fat that operates independently of uncoupling protein 1 (UCP1), the molecule traditionally considered the main driver of brown fat thermogenesis. The 2026 Nature paper adds the missing upstream piece: glycerol is what starts the whole process.
This line of investigation stretches back further. A 2022 study in Nature Metabolism first linked TNAP and CKB to heat production in fat cells through upstream signaling involving the ADRA1A receptor. That earlier work established the enzyme’s role in adipocyte thermogenesis but left open the question of what natural molecule actually turns TNAP on in living tissue. Glycerol, it turns out, was the answer.
Proof that TNAP is the real target
To confirm that TNAP was genuinely responsible for the calorie-burning effect, the McGill researchers used a chemical tool called SBI-425, a selective, orally bioavailable TNAP inhibitor first characterized in the Journal of Medicinal Chemistry. When they administered SBI-425 during respiration and thermogenesis experiments, it shut down the glycerol-stimulated heat production. Because SBI-425 was developed independently of the McGill lab’s work, its ability to block the effect provides a separate line of pharmacological evidence that TNAP is the genuine control point.
There is also a clinical precedent that supports TNAP’s biological importance. Strensiq (asfotase alfa), an enzyme replacement therapy approved for children with hypophosphatasia, works by supplementing deficient alkaline phosphatase activity so that bones can mineralize properly. Its FDA-approved labeling confirms that restoring TNAP function strengthens the skeleton. The McGill findings suggest the opposite direction could also hold therapeutic value: selectively boosting TNAP activity in fat tissue might increase calorie burning. But that possibility comes with a significant catch.
The double-edged biology of one enzyme
The same activation event that burns calories in brown fat also accelerates the deposition of mineral in bone. In the skeleton, that is a good thing. In blood vessels or joints, it is not. Vascular calcification, the hardening of artery walls, is a known contributor to cardiovascular disease, and ectopic mineralization in soft tissues is associated with chronic pain and reduced mobility.
The Nature paper identifies this dual function clearly but does not resolve whether it is possible to activate TNAP in fat cells without triggering unwanted mineralization elsewhere. Tissue-specific drug targeting is one of the hardest problems in pharmacology, and no published study has yet demonstrated a way to direct a TNAP activator exclusively to brown adipose tissue. Any future therapy built on this discovery will have to solve that problem before it reaches patients.
This tension is not a flaw in the research. It is the central biological reality that will determine whether the finding leads anywhere clinically. A drug that burns extra calories but stiffens arteries would be worse than useless.
What has not been tested yet
All of the thermogenesis and mineralization data reported so far come from animal models and cell-based experiments. No clinical trial has been announced for any compound designed to activate TNAP through the glycerol pocket for the purpose of increasing energy expenditure in humans. The McGill team has not disclosed a timeline for human testing, and no regulatory filing related to this mechanism has appeared in public databases as of June 2026.
Dosing is another open question. The futile creatine cycle burns energy, but how many additional calories glycerol-driven TNAP activation could produce in a person, and at what dose, has not been measured outside controlled laboratory conditions. Translating enzyme activation in isolated cells or rodents into safe, sustained metabolic effects in humans is a step that has tripped up countless drug candidates before.
Independent replication also matters. The institutional press coverage from McGill frames the discovery in optimistic terms, but no separate laboratory has yet published a confirmation of the glycerol-pocket mechanism. Nature’s peer review process provides a meaningful quality filter, and the SBI-425 experiments strengthen the case internally. Still, single-lab findings at this stage call for measured expectations rather than celebration.
One question readers may reasonably ask: does consuming glycerol as a supplement do anything useful? The short answer is that there is no evidence it would. Glycerol is already abundant in the body from normal fat breakdown, and swallowing more of it would not necessarily deliver it to brown fat cells in concentrations high enough to activate TNAP in a therapeutically meaningful way. The research points toward precision drug design, not dietary shortcuts.
Where this research stands in the larger picture
The strongest aspect of the McGill discovery is the chain of evidence behind it. Three peer-reviewed papers, published across four years in Nature Metabolism (2022), Nature Communications (2025), and Nature (2026), build on each other in a logical sequence. Each adds a distinct mechanistic layer: the enzyme’s role in fat-cell heat production, the futile creatine cycle it participates in, and finally the specific molecule that activates it. That kind of stepwise, internally consistent progression is what separates a credible research program from an isolated finding.
The pharmacological confirmation from SBI-425 adds further weight. Because the inhibitor was developed and characterized by a different group for a different purpose, its ability to block glycerol-stimulated thermogenesis argues against the possibility that the observed effect is a laboratory artifact.
But the history of metabolic drug development is littered with candidates that looked compelling in rodents and failed in humans because of toxicity, off-target effects, or underwhelming efficacy. The dual role of TNAP in both calorie burning and mineralization makes this particular target riskier than most. Researchers will need to demonstrate tissue-selective activation, establish safe dosing ranges in larger animals, and carefully monitor for vascular calcification before any human trial could proceed responsibly.
For readers who want to track how this develops, public databases such as PubMed and related NCBI resources are the primary places where new TNAP and glycerol studies will appear, from basic enzymology through early-stage clinical work. The signals to watch for: independent replication of the glycerol-pocket mechanism, dose-response studies in larger animal models, and any filings in clinical trial registries.
For now, the McGill group’s work is a mechanistic advance, not a medical breakthrough. It reveals that glycerol, a molecule the body produces constantly and discards routinely, can act as a molecular switch for an enzyme that straddles two of biology’s most important processes. Whether that switch can be flipped safely and selectively in patients is the question that will determine whether this discovery changes medicine or remains an elegant piece of basic science.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
